An easy way to handle microtiter plate stacks

Do you want to automate handling of microtiter plates.? Have a look at a very simple solution on how to handle them.

Ett livsviktigt organ – som sällan står i rampljuset

Njurarna består av mer än 40 typer av celler och har fler funktioner i kroppen än de flesta känner till. Julie Williams leder Astra Zenecas arbete inom preklini...

Bioarctics Alzheimerresultat hyllas i internationella medier

"Historiskt", "en möjlig seger", "fantastisk vändning". Nyheten om att svenskutvecklade lecanemab i en fas III-studie ser ut att kunna bromsa tidig Alzheimers h...

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Scale Up Your Image Analysis

ZEISS arivis Hub for accelerated analysis and faster results.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

The fast route to a safe insulin pen

Diabetes is on the rise worldwide with around ten million people developing the disease every year. Demand for insulin pens allowing patients to self-medicate i...

Conference recordings now available

Don't miss out on insights from leading experts.

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

Sobis giktläkemedel nådde primära mål i fas III

Svenska Sobi och amerikanska partnern Selecta rapporterar övergripande resultat från fas III-studier med giktläkemedlet SEL-212.

Life Science Sweden´s international issue is on its way

A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.

”Jumping genes” öppnar väg för ny behandling mot cancer

Alternativa sätt att hitta tumörantigen på tumörcellens yta kan bidra till att ta fram ny immunterapi.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

How to transport hydrogen - the BionicHydrogenBattery

Have you ever wondered how hydrogen should be transported and stored safely. Well, here is a solution for all who is interested in making a true infrastructure work.

Come see us at the upcoming events!

We have some upcoming events where you can see our latest products live!

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

Decades of research destroyed at KI – a hacker attack cannot be ruled out!

Years of research, together with half a billion Swedish krona, went up in smoke when the freezers at Karolinska Institutet overheated. The breakdown has now bee...

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

Mercodia AB

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

”De egenskaper vi har som kvinnliga ledare är otroligt viktiga”

För ett år sedan startades nätverket Vilda, Nätverk för ledande kvinnor inom life science, med syftet att stärka kvinnligt ledarskap. På fredagen höll nätverket...

Setback for pharmaceutical companies in the Zantac case

A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.